Given their promise, BiTEs against a range of tumor associated antigens have been generated9 including CD20,44 B-Cell maturation antigen (BCMA),45 epithelial cell adhesion molecule,46 and carcinoembryonic antigen (CEA),47 but the majority of clinical evaluation has so far been focused on patients with B cell malignancies with Blinatumomab. This evidence concerns the gene CEACAM5 and neoplasm.